rate (eGFR) by the four-variable Modification of Diet in Renal Disease formula was 64 ml/min/1.73 m 2 before transplantation, inter-quartile range (IQR) 54-78. After transplantation, the eGFR was 48 (IQR 37-61) at Year 1, and 41 at Year 10. The cumulative probability of eGFR <45 ml/min/1.73 m 2 was 45% at Year 1, 71% at Year 5 and 83% at Year 10. A multivariable logistic regression model was constructed for the development of eGFR <45 ml/min/1.73 m 2 by 3 years. The risk factors were postoperative renal replacement therapy for acute renal failure (ARF), P < 0.001; pretransplant diabetes, P = 0.005; increasing recipient age, P < 0.001; female recipient, P = 0.029; female donor, P = 0.04, but not CsA regimen. The cumulative probability of developing stage 5 CKD (eGFR <15) was 3% at Year 5 and 12% at Year 10. Although lower ciclosporin initial levels were associated with less renal
Introduction
Heart transplantation has become an established treatment for advanced heart failure. While medium-term survival rates are good, heart transplant recipients experience a number of complications related to pharmacological immunosuppression [1] . Chronic kidney disease (CKD) is an important long-term complication of all forms of non-renal organ transplantation [2] . This has been attributed to long-term treatment with calcineurin inhibitors (CNI) [3, 4] . Therapeutic drug monitoring to control CNI exposure has been used to limit acute CNI toxicity, but is unclear whether this strategy is effective in the long term [5] .
In 2000, the immunosuppression regimen used for heart transplantation at our centre was changed to one based on mycophenolate mofetil (MMF), and the target ciclosporin (CsA) levels used in the first year after heart transplantation were reduced [6] .
Here, we have retrospectively analysed the renal function for orthotopic cardiac transplant recipients at our centre from January 1995 to January 2005, to determine the incidence and risk factors for CKD including the influence of the CsA regimen.
Subjects and methods
We analysed 352 patients who underwent their first orthotopic cardiac transplant at Harefield Hospital from January 1995 to January 2005. We excluded patients who underwent combined organ transplants (heart-lung, heart-liver or heart-kidney), heterotopic heart transplants and patients with pretransplant cardiac amyloidosis. Patient characteristics are shown in Table 1 .
Estimated glomerular filtration rate was calculated according to the four-variable formula used in the Modification of Diet in Renal Disease Study (MDRD) [7] . As the majority of patients eventually developed National Kidney Foundation (NKF) stage 3 CKD we divided this into stages 3A and 3B for eGFRs of 45-59 and 30-44 ml/min/1.73 m 2 , respectively ( Table 2 ). Three immunosuppression protocols were used; (1995-1997) fulldose CsA (Neoral; Novartis Pharmaceuticals Frimley, UK) aiming initially for a 12-h trough level (C 12 ) of 250-350 ng/ml (Table 3) , azathioprine and corticosteroids, only using antithymocyte globulin (ATG) in cases where CsA was temporarily omitted because of post-operative renal failure; (1997) (1998) (1999) (2000) full-dose CsA after ATG induction therapy, azathioprine and corticosteroids; (2000-2005) ATG induction followed by lower dose CsA (aiming for C 12 levels of 200-300 ng/ml initially), combined with mycophenolate mofetil (MMF) and corticosteroids [6] . Ciclosporin was administered, orally, twice daily and doses were adjusted according to the morning predose trough level or 12-h CsA concentration in whole blood. For the purpose of the analysis, patients who received full-dose CsA (1995-2000) were aggregated as group 1 and patients receiving lower dose CsA therapy as group 2 (2000-2005) (Table 1) . Some patients were subsequently switched from CsA to tacrolimus or sirolimus mainly for repeated episodes of acute cellular rejection, renal dysfunction or CsA side effects (Table 1) . Permission to introduce the mycophenolate mofetil-based 
Statistical analysis
The two-sample t-test and chi-square tests were used as appropriate. Patient survival was estimated using the KaplanMeier method and groups compared using the log-rank test. Logistic regression was used to assess the factors for developing CKD stage 3B or worse at 3 years in both a univariable and multivariable analysis. Candidate risk factors with a P-value < 0.1 in the univariable analysis were considered for the multivariable model and a backward elimination procedure was used (the criterion used for inclusion in the final model was a P-value <0.05). A time-dependent Cox regression model was used to determine the impact of developing CKD stage 3B or worse on subsequent survival. We determined the cumulative incidence of CKD requiring renal replacement therapy using the Kaplan-Meier method.
Results
Patient characteristics are shown in Table 1 . Before transplantation, 40% of patients had an eGFR ≤59 ml/min/ 1.73 m 2 (stage 3A or worse) while 11% had an eGFR of ≤44 ml/min/1.73 m 2 (stage 3B or worse). None of the patients were receiving pretransplant renal replacement therapy. Twenty-three percent (82) of patients (22% group 1 versus 26% group 2) received temporary haemofiltration for acute renal failure (ARF) in the early post-operative period. The proportion of patients eventually switched from CsA to tacrolimus or sirolimus was similar in the two groups, 16.5% (38/231) group 1 versus 16.5% (20/121) group 2, P = 1.0. Thirteen percent (n = 46) of patients had pretransplant diabetes mellitus.
Patient survival and cardiac allograft function
Actuarial patient survival was 79% at 1 year, 77% at 3 years, 74% at 5 years and 62% at 10 years. There was no significant difference in survival between the two study groups; 77.5% group 1 versus 82.6% group 2 at 1 year; 75.3% versus 81.4% at 3 years; 71.8% versus 79.9% at 5 years, P = 0.2. The time-dependent Cox regression model did not find any evidence that developing CKD stage 3B or worse affected subsequent survival, P = 0.57. Survival following the development end-stage renal failure (stage 5, n = 17) was 80% at 1 year and 60% at 3 years.
Left ventricular ejection fraction by echocardiography was 74 ± 6% (275) at 1 year and 74 ± 4% (27) at 10 years. The incidence of biopsy-proven acute rejection (BPAR) episodes International Society for Heart and Lung Transplantation (ISHLT) grade 2R or worse at 1 year was higher in group 1 compared to group 2 (0.69 ± 1 versus 0.4 ± 0.76), P = 0.002, as were all treated clinical rejection episodes (1.3 ± 1.2 versus 0.7 ± 1) P < 0.0001.
CKD after transplantation
The pretransplantation mean serum creatinine concentration level was 111 ± SD 28 µmol/l. This rose to 145 ± 45 by Year 1, 157 ± 71 by Year 3, 161 ± 84 by Year 5 and 198 ± 185 by Year 10 ( Figure 1A ). Pretransplant mean eGFR was Figure 1B) . Comparison of the two groups showed a significantly higher proportion of CKD stage 3A or worse in group 1 at 3 months, 69% group 1 versus 44% group 2, P < 0.0001; at 1 year, 77% versus 65%, P = 0.006 and at 2 years, 79% versus 65%, P = 0.02. There was no difference at 3 years, 74% versus 72%, P = 0.8 or 5 years, 73% versus 67%, P = 0.5.
Some degree of renal impairment became almost universal; 93% of patients had an eGFR <60 ml/min/1.73 m 2 (stage 3A or worse) by 10 years (Figure 2 ). The cumulative incidence for an eGFR <45 ml/min/1.73 m 2 (stage 3B or worse) was 46% at 1 year, 65% at 3 years, 71% at 5 years and 83% at 10 years.
The cumulative probability of developing end-stage renal disease (ESRD, stage 5) was 3% by 5 years and 12% by 10 years (Figure 3 ). Seventeen patients needed renal replacement therapy, 11 were haemodialysed, 3 had peritoneal dialysis and 3 underwent renal transplantation (2 of whom were initially haemodialysed and 1 had a preemptive renal transplant).
Risk factors for CKD
The 12 candidate variables used in the univariable logistic regression model for CKD stage >3B or worse at 3 years were donor and recipient age, female donor and recipient, pretransplant diabetes mellitus, heart failure severity by New York Heart Association Class 4, pretransplant ischaemic cardiomyopathy, total cold ischaemia time, pretransplant mechanical or inotropic circulatory support, pretransplant renal function estimated by MDRD eGFR, temporary post-operative renal replacement therapy for ARF and lower 12-h CsA concentration in whole blood. The CsA regimen was not significantly related to the development of CKD stage 3B or worse (P = 0.4). The candidate variables for the multivariable analysis are shown in Table 5a .
The multivariable logistic regression model identified five risk factors for developing CKD stage 3B or worse at 3 years; these were post-operative renal replacement therapy for ARF, pretransplant diabetes mellitus, increasing recipient age, female recipient and female cardiac donor (Table 5b ). Pretransplant renal function by MDRD eGFR was significant in the univariable analysis, but not in the multivariable model when other factors have been taken into consideration, P = 0.3.
Discussion
We found that a substantial number of patients had an abnormal renal function prior to heart transplantation that could be related to their underlying heart failure or drug treatment. CKD was even more frequent after heart transplantation and that the incidence of serious renal impairment increased progressively with time. Similar findings have been reported from other studies [3, 4] . However, we found no evidence that reduction in CsA exposure during the first year after transplantation prevented long-term renal dysfunction. In this study, temporary renal replacement therapy for ARF, pretransplant diabetes mellitus, increasing recipient age and female cardiac donor were predictors of posttransplant CKD. Some of these factors have also been identified in other studies [2, [8] [9] [10] ; however, we also found that female transplant recipients were more at risk and to our knowledge this has not been previously reported in cardiac transplantation.
Incidence of CKD
Our study demonstrated a progressively increasing incidence of both moderate and severe CKD with time after transplantation. A similar pattern of CKD has been reported in other studies following organ transplantation. The incidence of CKD was significantly higher in group 1 (higher CsA exposure) compared with group 2 (lower CsA exposure) up to 2 years following transplantation, but this difference did not persist long term.
Fifty-four percent of the study patients had an eGFR <60 ml/min/1.73 m 2 by the first year. A decade following transplantation, the majority of our patients had some degree of renal dysfunction, 93% with an eGFR <60 ml/min/1.73 m 2 . The reported incidence of CKD after solid organ transplantation has varied between studies and with the organ transplanted. The criteria for assessing CKD have varied between studies (e.g. serum creatinine concentration, calculated eGFR or creatinine clearance by the Cockcroft and Gault formula). These differences in methodology make direct comparison between studies difficult. Nevertheless, the incidence of CKD reported here is higher than in some other studies.
Veillon et al. reported a 59% incidence of moderate CKD with an eGFR <70 ml/min per 1.73 m 2 at 1 year following heart transplantation [11] . Another study in cardiac and liver transplant recipients had a 56% incidence of moderate CKD with an eGFR <60 ml/min per 1.73 m 2 in the first year [12] . However, other studies reported a varied incidence of severe CKD with an eGFR ≤29 ml/min per 1.73 m 2 to be between 4.2 and 10.9% at 5 years following heart transplantation [2, 13] .
The incidence of CKD has varied in studies of other non-renal organ transplants. Canales et al. [14] reported that stage 3 CKD occurred in 54% of patients by 1 year and 59% of patients by 7 years in lung and heart-lung transplants. Kim et al. reported a 53% incidence of CKD (eGFR <60 ml/min/1.73 m 2 ) by 6 months following liver transplantation [15] . The cumulative incidence of CKD (defined as an eGFR ≤29 ml/min per 1.73 m 2 ) reported by Ojo et al. at 5 years following transplantation was 16% for lung transplantation, 18% liver and 23% intestinal transplantation [2] .
Incidence of end-stage renal disease
The cumulative incidence of ESRD in this study was lower than that reported in other studies. Twelve percent of patients in this study had developed ESRD by 10 years. Lubitz et al. reported a cumulative probability of ESRD of 4.5% at 5 years, 19.6% at 10 years and 44.6% at 15 years following heart transplantation [16] . The ISHLT reported a 27% cumulative probability of developing severe renal dysfunction (creatinine >2.5 mg/dl [≈220 µml/l], dialysis or renal transplant) by 5 years, 34% by 7 years and 42% by 10 years [17] .
Patient survival
Survival in our study group was similar to that reported nationally and internationally. The actuarial patient survival rate at 1 year, 79%, was similar to that reported for this era by ISHLT [1] , 81%, and UKCTA (United Kingdom 2007 Cardiothoracic Transplant Audit) [18] , 81%, as was survival at 10 years, 62% versus 50.5% ISHLT (UKCTA reported an 8 year survival of 61.8%). There was no significant difference in survival between our two study groups, although patients in group 2 had a shorter follow-up period.
The survival probability after the development of ESRD was 80% at 1 year and 60% at 3 years in our study. This is similar to the previous reports [19, 20] .
Incidence of acute allograft rejection and immunosuppression regimen
The introduction of CsA as an immunosuppressive agent dramatically improved survival after heart transplantation [21] ; however, nephrotoxicity has emerged as its most important adverse effect. MMF is known to provide superior prophylaxis against acute rejection when compared to azathioprine, therefore giving scope to lower target CsA levels [22] .
In group 2, the use of mycophenolate mofetil with lower CsA target levels did not result in increased biopsyproven acute cellular rejection episodes or clinical rejection episodes requiring treatment; in fact, the incidence of biopsy-proven and treated rejection episodes was lower in this group.
Ciclosporin exposure and CKD
We found no evidence that reduced CsA exposure had a beneficial effect on renal function by 3 years after transplantation despite some improvement at 1 year. One possible reason for this result is that, because of the need to maintain effective immunosuppression in patients with a life sustaining allograft, we only made a modest reduction in the CsA target levels. In addition, long-term maintenance levels that we used beyond 1 year were the same. Although CsA levels are clearly linked to acute nephrotoxicity, other factors may play an important role in the long term, including the duration of exposure and perhaps individual susceptibility [5] . Though CsA therapy has been recognized as one of the main contributory factors to the development of CKD, some studies have shown no correlation between post-operative renal function and CsA trough levels [23, 24] . There has also been conflicting evidence regarding the effectiveness of decreasing the dose of ciclosporin after renal insufficiency develops [25] . Ciclosporin withdrawal studies have demonstrated that even low-dose CsA can have an adverse effect on long-term renal function [26] . In our study, the multivariable analysis identified a number of risk factors for CKD but these did not include CsA exposure.
It is disappointing that reduced CsA exposure did not have a positive effect on long-term renal function. Calcineurin inhibitor-free immunosupression regimens may be more effective in this regard since renal function post-heart transplantation was better in the pre-ciclosporin era [3] . Although some small single-centre studies have investigated this approach [27] , there remains a concern about its safety following the abandonment of the 2007 Roche Cardiac 'Spare The Nephron' (STN) trial because of excess incidence of acute rejection [28] .
Risk factors for CKD
Renal dysfunction was common before heart transplantation, likely related to the haemodynamic effect of congestive heart failure, the renal effects of heart failure therapy and comorbidities such as diabetes mellitus [29, 30] . However, whilst pretransplant renal dysfunction was a univariable predictor of CKD, this effect was not evident in the multivariable analysis indicating that other factors play a dominant role in determining CKD after transplantation.
ARF after heart transplantation is mostly related to primary cardiac allograft dysfunction with impaired cardiac output and reduced renal perfusion as well as other factors such as aggressive diuresis, acute tubular necrosis, sepsis and the use of nephrotoxic or vasoconstrictor drugs [13] . Twenty-three percent of patients underwent haemofiltration for post-operative ARF following transplantation, and this was a significant predictor of CKD. The reported incidence of haemofiltration following solid organ transplantation has varied in different studies; 2-15% following heart transplantation, 8-10% following lung transplantation and 20-25% following liver transplantation [31] [32] [33] [34] [35] . The criteria for perioperative haemofiltration have not been standardized, and this may be one factor explaining the variation in the use of renal replacement therapy between different studies. It has been our practice to apply haemofiltration early in the presence of either oliguria, increased serum creatinine or lactate levels. Despite this liberal approach, we found that perioperative haemofiltration was associated with an increased risk of subsequent CKD. ARF has been linked to subsequent CKD in other heart transplantation studies [36, 37] .
We found that pretransplant diabetes mellitus was a risk factor for CKD, and this has also been shown in other studies. Thirteen percent of our study population had pretransplant diabetes compared with other studies where the incidence ranges between 6.5 and 17% [2, 16, 38] .
Increasing recipient age was a risk factor for future CKD similar to the ISHLT registry report [1] and other studies [9, 38] .
A female cardiac donor was identified as a risk factor for CKD, and this has not been reported before. However, Ostermann reported that a female-to-male, donor-to-recipient gender mismatch was a risk factor [37] and, since 80% of the transplant recipients in our study were male, this may represent the same phenomenon. A female-to-male, donorto-recipient gender mismatch has also been identified as a risk factor for primary cardiac allograft dysfunction particularly when there was also a size mismatch between donor and recipient [39] . Therefore, it seems possible that female donors are associated with worse perioperative haemodynamics and renal perfusion.
Our finding of an association between CKD and a female recipient is more difficult to explain. This has also been identified as a risk factor for CKD following lung transplantation [40] . Glomerular filtration rate is related to body size, but the MDRD formula provides an estimated eGFR that is corrected for the body surface area. Nevertheless, it seems possible that this finding could be related to the method we used for estimating GFR. However, female heart transplant recipients maybe more susceptible to CKD and further studies will be needed to clarify this matter.
Many of the risk factors that have been identified in this study are not modifiable. However, ARF may represent a therapeutic target that is amenable to intervention. Measures such as avoidance, as far as possible, of nephrotoxic and vasoconstrictor drugs may help to reduce the incidence of ARF [13] . Limiting ischaemic injury to the cardiac allograft by either reducing ischaemia time during the transplant procedure [41] or using other methods [42] to protect the cardiac allograft may help to reduce primary cardiac allograft dysfunction and consequent poor renal perfusion and thereby the incidence of ARF. Early application of temporary mechanical circulatory support in patients with primary cardiac allograft dysfunction prior to the development of ARF may also be of use [43] , although these strategies would need to be trialed prospectively.
Limitations
This is a single-centre observational study. Ciclosporin treatment was prospectively defined but was not allocated in a randomized way; however, we analysed the effect on long-term renal function using a multivariable model. We used the MDRD formula to evaluate the renal function of our study group. This formula has some limitations. It is based on serum creatinine concentration that may vary in relation to the patient's haemodynamic state or be affected by the patients' medication. It also uses the patients' weight, which in the transplant population increases gradually posttransplantation, probably with a lower muscle mass to fat ratio as a result of steroid therapy. Despite this the MDRD technique is currently one of the more reliable ways for assessing renal function [44] [45] [46] [47] .
Conclusion
Chronic kidney disease remains an important long-term complication of heart transplantation. As the number of long-term survivors increases, it is probable the burden of end-stage renal disease will also increase. The aetiology of CKD after heart transplantation is multifactorial, and although an early reduction of CsA exposure after transplantation improved renal function at 12 months, we found no evidence of long-term benefit. Whilst CsA reduction was not effective, non-CNI regimens may lead to better protection of renal function in the future, provided cardiac allograft rejection is adequately controlled. An alternative therapeutic objective maybe to reduce the incidence of acute renal failure by, perhaps, improving early post-operative cardiac allograft function or providing circulatory support in the early post-operative period.
